The pharmaceutical industry is at a pivotal crossroads, marked by an increasing integration of artificial intelligence (AI) into its research and development processes. This transformation is driven by strategic partnerships, technological advancements, and significant investments. Sanofi, a major player, exemplifies this trend with its recent partnership with OpenAI, aimed at accelerating drug discovery. This momentum is reinforced by similar initiatives across the sector, such as the $1.2 billion agreement between Exscientia and Bristol Myers Squibb (BMS) for AI-driven drug discovery.
Débloquez l'Analyse Complète
Accédez instantanément à nos insights exclusifs générés par IA, basés sur l'agrégation de centaines de sources sectorielles.
